Integragen (XPAR:ALINT) Short Interest

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XPAR:ALINT Integragen XPAR:ALINT
38 GF Score
Price €0.15
GF Value €0.42
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Integragen Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

XPAR:ALINT vs VRTX, REGN, ALNY: Short Interest Comparison

For the Biotechnology subindustry, Integragen's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Integragen Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Integragen's Short Interest distribution charts can be found below:

* The bar in red indicates where Integragen's Short Interest falls into.


XPAR:ALINT
38GF Score
Integragen XPAR:ALINT
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Integragen (XPAR:ALINT) Overvalued in 2026?

Based on GuruFocus' analysis, Integragen stock appears to be undervalued. The current stock price of €0.15 is trading 63.7% below its estimated GF Value™ of €0.42. GuruFocus considers Integragen to be Possible Value Trap.

Key valuation signals for XPAR:ALINT:

  • Short Interest:
  • GF Value™: €0.42 vs. price of €0.15 (63.7% below fair value)
  • GF Score™: 38/100 with 4 warning signs

No single metric tells the full story. See the XPAR:ALINT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Integragen Business Description

Other Exchanges 7N8:Germany
Address Genopole Campus 1 - Genavenir, 85 rue Henri Desbrueres, Evry, FRA, 91000
Integragen is engaged in the development of genetic biomarkers. It offers genomic and bioinformatic services, including clinical research, basic and human genetic research, bioinformatics and bioanalysis, agrigenomics, and genomics news, as well as genomic research tools and solutions to microbiologic researchers.
38GF Score

Get the complete analysis for XPAR:ALINT

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.15
Price
€0.42
GF Value